The n-Lorem Foundation is sponsoring a personalized antisense oligonucleotide (ASO) treatment targeting a specific genetic mutation (CHCHD10) in a single ALS patient. This study represents a novel approach to precision medicine in ALS, potentially positioning the foundation as a pioneer in the development of targeted therapies for rare genetic forms of the disease. The market for ALS treatments is competitive, with several therapies in development, but the personalized nature of this approach may differentiate it from existing options. Successful outcomes could lead to broader applications of ASO therapies in ALS and other genetic disorders, enhancing the foundation's strategic partnerships and funding opportunities.